Medicines Discovery Catapult (MDC) invested £500,000 each in two U.K. biotechs, funding Flip Therapeutics and Nascent Therapeutics through an Innovate UK-linked scheme. Flip is developing in vivo T cell reprogramming intended to generate long-lasting, controlled immune function for chronic autoimmune and inflammatory diseases including alopecia areata and psoriasis. Nascent Therapeutics, a University of East Anglia spinout, is focused on mitochondrial biology approaches for neurodegenerative diseases, cancer, and other age-related conditions. MDC said it will also provide translational drug discovery expertise and access to its advisor network. The funding underscores continued support for preclinical-to-early translational bets in immune reprogramming and metabolic/mitochondrial intervention strategies.